Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity

被引:10
作者
Zhang, Xinyu [1 ]
Teng, Xinzhi [1 ]
Zhang, Jiang [1 ]
Lai, Qingpei [1 ]
Cai, Jing [1 ,2 ]
机构
[1] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Hong Kong, Peoples R China
[2] Hong Kong Polytech Univ, Shenzhen Res Inst, Shenzhen, Peoples R China
关键词
Breast cancer; Radiomics; DCE-MRI; Treatment response prediction; NEOADJUVANT THERAPY; SURVIVAL; CHEMOTHERAPY; RADIOMICS;
D O I
10.1186/s13058-024-01836-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Early prediction of pathological complete response (pCR) is important for deciding appropriate treatment strategies for patients. In this study, we aimed to quantify the dynamic characteristics of dynamic contrast-enhanced magnetic resonance images (DCE-MRI) and investigate its value to improve pCR prediction as well as its association with tumor heterogeneity in breast cancer patients. Methods The DCE-MRI, clinicopathologic record, and full transcriptomic data of 785 breast cancer patients receiving neoadjuvant chemotherapy were retrospectively included from a public dataset. Dynamic features of DCE-MRI were computed from extracted phase-varying radiomic feature series using 22 CAnonical Time-sereis CHaracteristics. Dynamic model and radiomic model were developed by logistic regression using dynamic features and traditional radiomic features respectively. Various combined models with clinical factors were also developed to find the optimal combination and the significance of each components was evaluated. All the models were evaluated in independent test set in terms of area under receiver operating characteristic curve (AUC). To explore the potential underlying biological mechanisms, radiogenomic analysis was implemented on patient subgroups stratified by dynamic model to identify differentially expressed genes (DEGs) and enriched pathways. Results A 10-feature dynamic model and a 4-feature radiomic model were developed (AUC = 0.688, 95%CI: 0.635-0.741 and AUC = 0.650, 95%CI: 0.595-0.705) and tested (AUC = 0.686, 95%CI: 0.594-0.778 and AUC = 0.626, 95%CI: 0.529-0.722), with the dynamic model showing slightly higher AUC (train p = 0.181, test p = 0.222). The combined model of clinical, radiomic, and dynamic achieved the highest AUC in pCR prediction (train: 0.769, 95%CI: 0.722-0.816 and test: 0.762, 95%CI: 0.679-0.845). Compared with clinical-radiomic combined model (train AUC = 0.716, 95%CI: 0.665-0.767 and test AUC = 0.695, 95%CI: 0.656-0.714), adding the dynamic component brought significant improvement in model performance (train p < 0.001 and test p = 0.005). Radiogenomic analysis identified 297 DEGs, including CXCL9, CCL18, and HLA-DPB1 which are known to be associated with breast cancer prognosis or angiogenesis. Gene set enrichment analysis further revealed enrichment of gene ontology terms and pathways related to immune system. Conclusion Dynamic characteristics of DCE-MRI were quantified and used to develop dynamic model for improving pCR prediction in breast cancer patients. The dynamic model was associated with tumor heterogeniety in prognostic-related gene expression and immune-related pathways.
引用
收藏
页数:12
相关论文
共 50 条
[21]  
Li Q, 2021, CANCER MANAG RES, V13, P5053, DOI [10.2147/CMAR.S304547, 10.2741/CMAR.S304547]
[22]   Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge [J].
Li, Wen ;
Partridge, Savannah C. ;
Newitt, David C. ;
Steingrimsson, Jon ;
Marques, Helga S. ;
Bolan, Patrick J. ;
Hirano, Michael ;
Bearce, Benjamin Aaron ;
Kalpathy-Cramer, Jayashree ;
Boss, Michael A. ;
Teng, Xinzhi ;
Zhang, Jiang ;
Cai, Jing ;
Kontos, Despina ;
Cohen, Eric A. ;
Mankowski, Walter C. ;
Liu, Michael ;
Ha, Richard ;
Pellicer-Valero, Oscar J. ;
Maier-Hein, Klaus ;
Rabinovici-Cohen, Simona ;
Tlusty, Tal ;
Ozery-Flato, Michal ;
Parekh, Vishwa S. ;
Jacobs, Michael A. ;
Yan, Ran ;
Sung, Kyunghyun ;
Kazerouni, Anum S. ;
Dicarlo, Julie C. ;
Yankeelov, Thomas E. ;
Chenevert, Thomas L. ;
Hylton, Nola M. .
RADIOLOGY-IMAGING CANCER, 2024, 6 (01)
[23]  
Li Wen, 2022, TCIA, DOI 10.7937/TCIA.D8Z0-9T85
[24]   CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer [J].
Lin, Ling ;
Chen, Yong-Song ;
Yao, Yan-Dan ;
Chen, Jing-Qi ;
Chen, Jia-Ning ;
Huang, Song-Yin ;
Zeng, Yun-Jie ;
Yao, He-Rui ;
Zeng, Si-Hai ;
Fu, Yong-Shui ;
Song, Er-Wei .
ONCOTARGET, 2015, 6 (33) :34758-34773
[25]   Chemokines and chemokine receptors: A new strategy for breast cancer therapy [J].
Liu, Hui ;
Yang, Zhenjiang ;
Lu, Wenping ;
Chen, Zhen ;
Chen, Lianyu ;
Han, Shuyan ;
Wu, Xiaoyu ;
Cai, Tiange ;
Cai, Yu .
CANCER MEDICINE, 2020, 9 (11) :3786-3799
[26]   catch22: CAnonical Time-series CHaracteristics Selected through highly comparative time-series analysis [J].
Lubba, Carl H. ;
Sethi, Sarab S. ;
Knaute, Philip ;
Schultz, Simon R. ;
Fulcher, Ben D. ;
Jones, Nick S. .
DATA MINING AND KNOWLEDGE DISCOVERY, 2019, 33 (06) :1821-1852
[27]  
Lundberg SM, 2017, ADV NEUR IN, V30
[28]   Overexpressed PseudogeneHLA-DPB2Promotes Tumor Immune Infiltrates by RegulatingHLA-DPB1and Indicates a Better Prognosis in Breast Cancer [J].
Lyu, Lijuan ;
Yao, Jia ;
Wang, Meng ;
Zheng, Yi ;
Xu, Peng ;
Wang, Shuqian ;
Zhang, Dai ;
Deng, Yujiao ;
Wu, Ying ;
Yang, Si ;
Lyu, Jun ;
Guan, Feng ;
Dai, Zhijun .
FRONTIERS IN ONCOLOGY, 2020, 10
[29]   Breast MRI: guidelines from the European Society of Breast Imaging [J].
Mann, R. M. ;
Kuhl, C. K. ;
Kinkel, K. ;
Boetes, C. .
EUROPEAN RADIOLOGY, 2008, 18 (07) :1307-1318
[30]  
Newitt David C, 2021, TCIA